Post‐transcriptional gene silencing targets and degrades mRNA transcripts, silencing the
expression of specific genes. RNA interference technology, using synthetic structurally well …

Recent years have seen unprecedented activity in the development of RNA-silencing
oligonucleotide therapeutics for metabolic diseases. Improved oligonucleotide design and …

Hypertension remains the leading cause of cardiovascular disease and premature death
globally, affecting half of US adults. A high proportion of hypertensive patients exhibit …

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …

Arterial hypertension affects about one third of the German population with a prevalence
increasing with age up to 60%. Globally, more than a quarter gedoppelt of the population …

During pregnancy, the risk of maternal and fetal adversities increases due to physiological
changes, genetic predispositions, environmental factors, and infections. Unfortunately …